Beijing SL Pharmaceutical Co Ltd (002038) — Net Asset Quality Index
Beijing SL Pharmaceutical Co Ltd (002038) has a Net Asset Quality Index of 87.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.84 Billion minus total liabilities of CN¥735.46 Million yields net assets of CN¥5.10 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Beijing SL Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Beijing SL Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2001–2025)
This chart shows how Beijing SL Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 25 annual periods from 2001 to 2025. As of March 2026, the index stands at 87.4%, representing net assets of CN¥5.10 Billion against total assets of CN¥5.84 Billion CNY. See 002038 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Beijing SL Pharmaceutical Co Ltd (2001–2025)
The table below presents the year-by-year Net Asset Quality Index for Beijing SL Pharmaceutical Co Ltd from 2001 to 2025, covering 25 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Beijing SL Pharmaceutical Co Ltd market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.4% | CN¥5.19 Billion | CN¥6.07 Billion | CN¥883.49 Million | ▼ -7.9 pp |
| 2024 | 93.3% | CN¥5.58 Billion | CN¥5.98 Billion | CN¥398.37 Million | ▲ +0.8 pp |
| 2023 | 92.5% | CN¥5.81 Billion | CN¥6.28 Billion | CN¥467.72 Million | ▼ -0.7 pp |
| 2022 | 93.3% | CN¥5.48 Billion | CN¥5.88 Billion | CN¥396.60 Million | ▲ +0.8 pp |
| 2021 | 92.5% | CN¥5.33 Billion | CN¥5.76 Billion | CN¥434.23 Million | ▲ +0.1 pp |
| 2020 | 92.4% | CN¥4.98 Billion | CN¥5.39 Billion | CN¥410.09 Million | ▲ +0.1 pp |
| 2019 | 92.3% | CN¥4.82 Billion | CN¥5.22 Billion | CN¥403.76 Million | ▲ +1.7 pp |
| 2018 | 90.6% | CN¥4.52 Billion | CN¥4.99 Billion | CN¥469.73 Million | ▼ -3.2 pp |
| 2017 | 93.8% | CN¥4.30 Billion | CN¥4.59 Billion | CN¥285.67 Million | ▼ -2.5 pp |
| 2016 | 96.3% | CN¥3.93 Billion | CN¥4.08 Billion | CN¥151.19 Million | ▲ +0.2 pp |
| 2015 | 96.1% | CN¥3.61 Billion | CN¥3.76 Billion | CN¥148.40 Million | ▲ +0.2 pp |
| 2014 | 95.8% | CN¥3.18 Billion | CN¥3.32 Billion | CN¥137.92 Million | ▲ +0.4 pp |
| 2013 | 95.5% | CN¥2.59 Billion | CN¥2.71 Billion | CN¥123.09 Million | ▲ +0.2 pp |
| 2012 | 95.3% | CN¥2.11 Billion | CN¥2.22 Billion | CN¥105.17 Million | ▼ -1.8 pp |
| 2011 | 97.1% | CN¥1.69 Billion | CN¥1.74 Billion | CN¥50.52 Million | ▲ +0.1 pp |
| 2010 | 97.0% | CN¥1.21 Billion | CN¥1.25 Billion | CN¥37.22 Million | ▲ +0.6 pp |
| 2009 | 96.4% | CN¥983.06 Million | CN¥1.02 Billion | CN¥36.75 Million | ▼ -0.3 pp |
| 2008 | 96.7% | CN¥762.61 Million | CN¥788.52 Million | CN¥25.91 Million | ▲ +2.6 pp |
| 2007 | 94.1% | CN¥551.93 Million | CN¥586.63 Million | CN¥34.71 Million | ▲ +1.8 pp |
| 2006 | 92.3% | CN¥426.20 Million | CN¥461.61 Million | CN¥35.41 Million | ▼ -1.9 pp |
| 2005 | 94.2% | CN¥382.49 Million | CN¥405.91 Million | CN¥23.42 Million | ▲ +1.5 pp |
| 2004 | 92.7% | CN¥361.45 Million | CN¥389.83 Million | CN¥28.38 Million | ▲ +16.9 pp |
| 2003 | 75.8% | CN¥115.05 Million | CN¥151.83 Million | CN¥36.78 Million | ▼ -7.5 pp |
| 2002 | 83.2% | CN¥85.61 Million | CN¥102.84 Million | CN¥17.23 Million | ▼ -2.7 pp |
| 2001 | 85.9% | CN¥66.29 Million | CN¥77.13 Million | CN¥10.84 Million | — |